Pfizer Limited (NSE:PFIZER)

Market Cap	174.53B -26.9%
Revenue (ttm)	25.70B +10.7%
Net Income	7.35B -9.1%
EPS	160.70 -9.1%
Shares Out	45.75M
PE Ratio	23.74
Forward PE	20.76
Dividend	75.00 (1.97%)
Ex-Dividend Date	Jul 17, 2026

Volume	11,655
Open	3,870.00
Previous Close	3,852.20
Day's Range	3,802.00 - 3,870.10
52-Week Range	3,792.10 - 5,578.50
Beta	0.13
Analysts	Buy
Price Target	6,008.50 (+57.49%)
Est. Earnings	Nov 12, 2026

About Pfizer

Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers therapy area and products, such as vaccines, injectables and anti-infectives, inflammation and immunology, and internal medicine for cardiovascular care, oncology, respiratory, multivitamins and multimineral, neuroscience, women's health, gastroenterology, pain management, and nutrition, addressing. The company also offers anti-infectives services to hospitals and nursing homes. It sells its products t...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1950
• Employees: 1,244
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: PFIZER

Financial Performance

In fiscal year 2026, Pfizer's revenue was 25.20 billion, an increase of 10.45% compared to the previous year's 22.81 billion. Earnings were 7.22 billion, a decrease of -5.88%.

Analyst Summary

According to 4 analysts, the average rating for PFIZER stock is "Buy." The 12-month stock price target is ₹6,009, which is an increase of 57.49% from the latest price.

Price Target

₹6,009

(57.49% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 7, 2026

Data Sources Report a data error